Pharma Pulse 2/21/25: Challenges in Developing T Cell Engagers, Vietnam War Vets Are Still Battling PTSD, Along With Chronic Illnesses & more

Challenges in Developing T Cell Engagers

Ian Chan, CEO of Abpro, discusses the advantages of their DiversImmune and MultiMab platforms for antibody discovery and engineering. Abpro's platform can create novel antibodies at industry-leading speeds, which are then reassembled into custom configurations for therapeutic purposes. They have developed bispecific antibodies, particularly T cell engagers for oncology, which are effective against solid tumors. Abpro's lead oncology program for breast cancer, in partnership with Celltrion, is advancing through clinical phases. Additionally, they have an eye care molecule targeting AMD and DME. The recent NASDAQ listing will aid in accelerating R&D and commercialization efforts. Collaborations, like the one with Celltrion, have been instrumental in the company's success.

Many Aging Vietnam War Vets Are Still Battling PTSD, Along With Chronic Illnesses, That Combat Exposure May Make More Likely, New Research Finds

Two groundbreaking studies shed light on combat’s lasting physical and psychological damage more than 50 years on.

AI Data Center With Up to 3 Gigawatts of Power Is Envisioned for South Korea

Few global facilities possess more than a gigawatt of power, making electricity for AI computing increasingly scarce.

Hims & Hers Acquires At-Home Lab Testing Facility, Expanding Capabilities to Ultimately Include Affordable Whole Body Testing for Subscribers

Hims & Hers Health, Inc. plans to introduce at-home lab testing through its platform. The new capability will empower customers to take control of their health with deeper insights and enable providers to access a breadth of data and biomarkers that can help identify risk of disease before it develops, for more precise clinical decision-making.

Lowenstein Sandler LLP on LinkedIn

How will tariffs and federal funding shifts impact the pharmaceutical industry? Lowenstein FDA Regulatory Chair Jim Shehan continues his conversation with Pharmaceutical Commerce Magazine, discussing the potential ripple effects on drug prices and NIH-funded research.

Watch the full interview: https://bit.ly/3CXvIdF
Read Jim’s bio: https://lnkd.in/dfVXMGeP

#fda #drugprices #pharmaindustry #pharmaceuticals #foodanddrug

Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs